Maharashtra’s Food and Drug Administration (FDA) has issued a statewide ban on Coldrif cough syrup, following alarming findings that linked the medicine to multiple child fatalities in neighboring states. The decision comes after laboratory analysis revealed traces of diethylene glycol, a toxic industrial solvent known to cause severe poisoning when ingested.

Statewide Ban Follows Contamination Discovery

The Maharashtra FDA confirmed that the ban applies specifically to Batch No. SR-13 of Coldrif syrup. The move was prompted by reports connecting the product to 14 child deaths in nearby regions. Officials stated that the contamination posed a serious public health risk, leading to immediate withdrawal of the affected batch from all distribution channels across the state.

Diethylene Glycol Identified as Toxic Agent

Investigations revealed that diethylene glycol—a chemical typically used in industrial applications such as antifreeze—was present in the syrup formulation. Even small amounts of this compound can cause kidney failure, neurological damage, and death, particularly among children. Health authorities emphasized that pharmaceutical-grade glycerin substitutes must meet stringent purity standards to prevent such tragedies.

Nagpur FDA Acts Against Anset Syrup

In a parallel development, Nagpur’s FDA imposed restrictions on another product, Anset syrup, after receiving complaints and tip-offs from families who reported adverse effects. Officials initiated precautionary testing and temporarily halted its sale until safety verification is complete. This dual enforcement effort reflects growing vigilance among regulators toward ensuring medicine quality and consumer safety across the region.

Coordinated Efforts to Prevent Further Losses

Authorities have intensified inspections at manufacturing facilities and distribution centers associated with both syrups. Samples have been collected for detailed analysis, while health officers are conducting awareness drives among pharmacists and healthcare providers to identify any remaining stock in circulation. The FDA reiterated its commitment to holding manufacturers accountable for lapses in quality control and adherence to safety protocols.

Public Health Response and Safety Advisory

Medical professionals have urged parents and caregivers to immediately discontinue use of Coldrif or Anset syrups if purchased recently and consult healthcare providers for safe alternatives. Pharmacies have been instructed to return existing stock to suppliers pending further notice from regulatory authorities. The FDA also advised citizens to verify drug batch numbers before purchase and report any suspected counterfeit or contaminated medicines through official helplines.

The ban on Coldrif syrup underscores the critical importance of maintaining strict pharmaceutical oversight in India’s vast drug manufacturing network. As investigations continue, regulators aim to strengthen testing procedures and ensure that similar incidents do not recur, safeguarding public trust in essential medicines nationwide.